
Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL Injection for intravenous use

TOGETHER

ready for the next treatment option

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.



As you get ready to start treatment, you may have questions or want to learn more about the option of using MARGENZA plus chemotherapy.

Here you'll find information that can help you better understand what to expect from MARGENZA, including **treatment benefits, how it works, how it's given, and more.**

Important Safety Information

MARGENZA can cause serious side effects, including:

- Heart problems that may affect your heart's ability to pump blood.
- Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA.

Please see Important Safety Information on pages 6-7, and full [Prescribing Information](#), including Boxed Warning.



MARGENZA is an infusion that was approved by the FDA in 2020


What does MARGENZA treat?

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.


What does it mean to have HER2-positive metastatic breast cancer?

Some breast cancer cells have too much of a protein called human epidermal growth factor receptor 2, or HER2. This protein tells the cancer cells to grow. About 1 in 5 people with breast cancer have HER2-positive breast cancer.

How MARGENZA works



MARGENZA targets the HER2-positive receptors and may help stop the chemical signals that tell the cancer cells to grow.



MARGENZA was engineered to improve how your body's immune system works, enabling it to destroy the cancer cells.

FDA=US Food and Drug Administration.

Important Safety Information

What is the most important information I should know about MARGENZA?

MARGENZA can cause serious side effects, including:

- **Heart problems that may affect your heart's ability to pump blood.** Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or discontinue treatment with MARGENZA.
 - Tell your healthcare provider right away if you get any of the following signs and symptoms: new or worsening shortness of breath, coughing, feeling tired, swelling of the ankles or legs, swelling of the face, irregular heart beat or palpitations, sudden weight gain of more than 5 pounds in 24 hours, dizziness or feeling light-headed, or loss of consciousness.
- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA. Exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.
 - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with MARGENZA.
 - Birth control should be used while receiving MARGENZA and for 4 months after your last dose of MARGENZA.

Please see Important Safety Information on pages 6-7, and full [Prescribing Information](#), including Boxed Warning.

What to expect

MARGENZA offers a chance for more time without cancer growing and spreading.

In a clinical trial of 536 patients, people treated with MARGENZA plus chemotherapy lived longer without the cancer growing or spreading than people who were treated with trastuzumab plus chemotherapy.

MARGENZA plus chemotherapy lowered the chance of disease progression by 24% compared with trastuzumab plus chemotherapy

Median* time without cancer growing or spreading

5.8 months
MARGENZA plus chemotherapy
(266 people)

4.9 months
Trastuzumab plus chemotherapy
(270 people)

*Median is the middle number in a group of numbers that are listed from lowest to highest.

There was not a statistically significant difference in how long patients lived when comparing MARGENZA + chemotherapy and trastuzumab + chemotherapy.

Patients enrolled in the study had metastasis in the bone, lymph node, lung, liver, breast, skin, or brain. The median age of participants in the study was 56 years (age range 27-86 years), and 78% of patients were less than 65 years old.

Important Safety Information

What are other possible serious side effects of MARGENZA?

Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.

Please see Important Safety Information on pages 6-7, and full [Prescribing Information](#), including Boxed Warning.

**Margenza**[®]
(margetuximab-cmkb)
250 mg/10 mL Injection for intravenous use

A choice of chemotherapy

MARGENZA is FDA-approved to be used in combination with chemotherapy. That gives your doctor the flexibility to consider various chemotherapy options based on your individual needs, past treatments, and experiences.

In the clinical trial where MARGENZA was studied, MARGENZA was used with a choice of 4 chemotherapies, which included **capecitabine, eribulin, gemcitabine, and vinorelbine**.



Talk to your
doctor about
chemotherapy
options with
MARGENZA

Important Safety Information

What are the most common side effects of MARGENZA in combination with chemotherapy?

The most common side effects with MARGENZA in combination with chemotherapy are

- fatigue/weakness
- nausea
- diarrhea
- vomiting
- constipation
- headache
- fever
- hair loss
- abdominal pain
- peripheral neuropathy (weakness, numbness, pain, and/or tingling in hands and feet)
- joint and muscle pain
- cough
- decreased appetite
- shortness of breath
- infusion-related reactions
- redness/swelling and pain on the palms of the hands and soles of the feet (hand-foot syndrome)
- pain in arms and legs

These are not all the possible side effects of MARGENZA. Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.

You are encouraged to report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).

Please see Important Safety Information on pages 6-7, and full [Prescribing Information](#), including Boxed Warning.

Here's how you'll get MARGENZA

Dose  Intravenous 15 mg/kg Given at an infusion center	First Infusion  Over 120 minutes	Later Infusions  Over 30 minutes (minimum)	 Every 21 days
---	--	--	--

On days when both MARGENZA and chemotherapy are to be administered, MARGENZA may be administered immediately after chemotherapy completion.

MARGENZA Access Support is here to help with copay and financial assistance

A dedicated support specialist can help you enroll.

 Call [1-844-MED-MGNX \(1-844-633-6469\)](tel:1-844-MED-MGNX), Monday-Friday, 9 AM to 7 PM ET

 Visit www.MARGENZA.com

→ If you have questions about your cancer or treatment plan, be sure to talk with your doctor. To learn more, visit www.MARGENZA.com

Important Safety Information

Before you receive MARGENZA, tell your doctor if you are breastfeeding. It is not known if MARGENZA could pass into breast milk and harm your baby.

Please see Important Safety Information on pages 6-7, and full [Prescribing Information](#), including Boxed Warning.


Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL Injection for intravenous use

Important Safety Information

What is the most important information I should know about MARGENZA?

MARGENZA can cause serious side effects, including:

- **Heart problems that may affect your heart's ability to pump blood.** Your doctor will run tests to monitor your heart function before and during treatment with MARGENZA. Based on test results, your doctor may hold or discontinue treatment with MARGENZA.
 - Tell your healthcare provider right away if you get any of the following signs and symptoms: new or worsening shortness of breath, coughing, feeling tired, swelling of the ankles or legs, swelling of the face, irregular heart beat or palpitations, sudden weight gain of more than 5 pounds in 24 hours, dizziness or feeling light-headed, or loss of consciousness.
- **Harm to your unborn baby.** Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA. Exposure to MARGENZA during pregnancy or within 4 months prior to conception can result in fetal harm.
 - If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with MARGENZA.
 - Birth control should be used while receiving MARGENZA and for 4 months after your last dose of MARGENZA.

What are other possible serious side effects of MARGENZA?

Infusion-related reactions. MARGENZA is a medicine that is delivered into a vein through a needle as an infusion. MARGENZA has been associated with infusion-related reactions which can include fever, chills, joint pain, cough, dizziness, tiredness, nausea, vomiting, headache, sweating, fast heart rate, low blood pressure, itching, rash, hives, and shortness of breath. Your healthcare team will monitor you during treatment with MARGENZA and may slow or stop your infusion if you have side effects. You may need to permanently stop MARGENZA if you have a severe infusion reaction.

Please see additional Important Safety Information on the following page, and full [Prescribing Information](#), including **Boxed Warning**.

Important Safety Information (cont'd)

Before you receive MARGENZA, tell your doctor

if you are breastfeeding. It is not known if MARGENZA could pass into breast milk and harm your baby.

What are the most common side effects of MARGENZA in combination with chemotherapy?

The most common side effects with MARGENZA in combination with chemotherapy are fatigue/weakness, nausea, diarrhea, vomiting, constipation, headache, fever, hair loss, abdominal pain, peripheral neuropathy (weakness, numbness, pain, and/or tingling in hands and feet), joint and muscle pain, cough, decreased appetite, shortness of breath, infusion-related reactions, redness/swelling and pain on the palms of the hands and soles of the feet (hand-foot syndrome), and pain in arms and legs.

You are encouraged to report side effects to the FDA at [\(800\) FDA-1088](tel:800-FDA-1088) or www.fda.gov/medwatch or to MacroGenics at [\(844\)-MED-MGNX \(844-633-6469\)](tel:844-MED-MGNX).

These are not all the possible side effects of MARGENZA. Your doctor may stop treatment if serious side effects happen. Be sure to contact your healthcare team right away if you have questions or are worried about any side effects.

What does MARGENZA treat?

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Please see full [Prescribing Information](#), including **Boxed Warning**.

Talk to your doctor about MARGENZA



Targets HER2-positive receptors and may help stop the chemical signals that tell the cancer cells to grow

↓ 24%

Patients taking MARGENZA plus chemotherapy had a median of 5.8 months without cancer growing or spreading vs. 4.9 months for patients taking trastuzumab (a 24% reduction in risk of disease progression)



Provides the flexibility to consider various chemotherapy options based on your individual needs, past treatment, and experiences

What does MARGENZA treat?

MARGENZA is a prescription medicine approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Important Safety Information

MARGENZA can cause serious side effects, including:

- Heart problems that may affect your heart's ability to pump blood.
- Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with MARGENZA.

Please see Important Safety Information on pages 6-7, and full [Prescribing Information](#), including Boxed Warning.

Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL Injection for intravenous use

Access Support

is here to help

Copay and financial assistance are available for eligible patients.
A dedicated support specialist can help you enroll.



Call [1-844-MED-MGNX \(1-844-633-6469\)](tel:1-844-MED-MGNX),
Monday-Friday, 9 AM to 7 PM ET



Visit www.MARGENZA.com



MARGENZA is a registered trademark of MacroGenics, Inc.
All other trademarks or registered trademarks are the property of their respective owners.
©2022 MacroGenics, Inc. All Rights Reserved. 11/2022 US-COM-MGA-2200112

Margenza[®]
(margetuximab-cmkb)
250 mg/10 mL Injection for intravenous use